Fiera Capital Corp bought a new position in Irhythm Technologies Inc (NASDAQ:IRTC) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 300,526 shares of the company’s stock, valued at approximately $23,766,000. Fiera Capital Corp owned 1.21% of Irhythm Technologies at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. Advisor Group Inc. lifted its position in Irhythm Technologies by 403.1% during the 2nd quarter. Advisor Group Inc. now owns 805 shares of the company’s stock valued at $63,000 after acquiring an additional 645 shares during the period. Quantamental Technologies LLC lifted its position in Irhythm Technologies by 78.5% during the 1st quarter. Quantamental Technologies LLC now owns 1,423 shares of the company’s stock valued at $107,000 after acquiring an additional 626 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Irhythm Technologies by 93.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,825 shares of the company’s stock valued at $144,000 after acquiring an additional 882 shares during the period. Bank of Montreal Can lifted its position in Irhythm Technologies by 3,879.2% during the 2nd quarter. Bank of Montreal Can now owns 2,109 shares of the company’s stock valued at $167,000 after acquiring an additional 2,056 shares during the period. Finally, Rehmann Capital Advisory Group lifted its position in Irhythm Technologies by 2,617.6% during the 1st quarter. Rehmann Capital Advisory Group now owns 2,935 shares of the company’s stock valued at $220,000 after acquiring an additional 2,827 shares during the period.
A number of research analysts recently issued reports on IRTC shares. Zacks Investment Research cut shares of Irhythm Technologies from a “hold” rating to a “sell” rating in a research report on Friday, August 2nd. BidaskClub cut shares of Irhythm Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, July 30th. BTIG Research set a $90.00 price target on shares of Irhythm Technologies and gave the company a “buy” rating in a research report on Wednesday, July 31st. Finally, JPMorgan Chase & Co. lifted their price target on shares of Irhythm Technologies from $110.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $99.00.
In other Irhythm Technologies news, Director Merz Cathleen Noel Bairey sold 1,209 shares of the company’s stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $76.40, for a total value of $92,367.60. Following the completion of the transaction, the director now directly owns 3,844 shares in the company, valued at $293,681.60. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Matthew C. Garrett sold 27,569 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $76.83, for a total transaction of $2,118,126.27. Following the completion of the transaction, the chief financial officer now owns 29,101 shares of the company’s stock, valued at $2,235,829.83. The disclosure for this sale can be found here. 3.85% of the stock is currently owned by insiders.
Shares of Irhythm Technologies stock opened at $74.52 on Thursday. The company has a debt-to-equity ratio of 2.53, a quick ratio of 2.59 and a current ratio of 2.66. The stock has a market capitalization of $1.84 billion, a PE ratio of -39.43 and a beta of 1.77. Irhythm Technologies Inc has a 52-week low of $58.99 and a 52-week high of $98.37. The company has a 50-day simple moving average of $76.92 and a two-hundred day simple moving average of $78.04.
Irhythm Technologies (NASDAQ:IRTC) last issued its earnings results on Wednesday, July 31st. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.02). The firm had revenue of $53.30 million during the quarter, compared to analysts’ expectations of $49.89 million. Irhythm Technologies had a negative return on equity of 76.47% and a negative net margin of 24.45%. The firm’s quarterly revenue was up 50.1% on a year-over-year basis. During the same period last year, the firm posted ($0.51) earnings per share. As a group, equities research analysts forecast that Irhythm Technologies Inc will post -1.54 EPS for the current fiscal year.
Irhythm Technologies Company Profile
iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.
Featured Story: Resistance Level
Want to see what other hedge funds are holding IRTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Irhythm Technologies Inc (NASDAQ:IRTC).
Receive News & Ratings for Irhythm Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Irhythm Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.